LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


Ozoralizumab’s OLE Results Suggest Several Competitive Advantages Over Blockbuster Humira


« Back to News


-Positive Efficacy Results Suggest the Possibility for Individualized Treatment-

-Superior Immunogenicity Profile Demonstrated-


Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx

Last week, Ablynx NV (Euronext Brussels: ABLX), presented positive results of the Phase 2 open-label extension (OLE) study of ozoralizumab in patients with rheumatoid arthritis. The efficacy results were comparable to other TNFα drugs and the secondary measures were quite compelling as they suggest several advantages over TNFα blockers, including the $8.2B RA blockbuster, Humira.

Previously, Ablynx’ ozoralizumab (ATN-103) achieved proof of concept and met the primary endpoint in a Phase 2 study with 72% (p=0.006) and 37% (p=0.047) of subjects achieving an ACR20 and ACR50 response at the 80mg Q4W dose after 16 weeks, respectively. On Monday June 25, Ablynx reported positive results from 85% (n=266) of the subjects that were enrolled in the previous two studies.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design